DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening and Pharmacological Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 bioactive compounds that are clinically approved by regulatory agencies such as the FDA, EMA, HMA, CFDA, and PMDA, or are listed in pharmacopeias. All compounds are pre-dissolved at 10 mM in DMSO and stable for up to 24 months at -80°C, ensuring reproducibility and ease of use for high-throughput and high-content screening (HTS/HCS) workflows. The library supports drug repositioning and pharmacological target identification, with representative mechanisms including receptor agonists/antagonists, enzyme inhibitors, and ion channel modulators. Recent studies have used similar libraries to identify novel anti-leukemia mechanisms of clinically approved drugs (Yang et al., 2025, DOI). APExBIO provides this resource in flexible formats, including 96-well plates and 2D barcoded tubes.

Biological Rationale

High-throughput screening (HTS) of clinically approved compound libraries accelerates the discovery of new therapeutic uses (drug repositioning) and uncovers novel pharmacological targets. The DiscoveryProbe™ FDA-approved Drug Library provides a curated set of compounds with well-characterized safety and bioactivity profiles, enabling rapid translation of findings into preclinical and clinical settings. The inclusion of drugs with diverse mechanisms—such as doxorubicin (antineoplastic), metformin (antihyperglycemic), and atorvastatin (lipid-lowering)—broadens the scope for studying disease pathways, including oncology and neurodegenerative disorders. By focusing on compounds already approved by major agencies (FDA, EMA, HMA, CFDA, PMDA), the library minimizes translational barriers and facilitates cross-indication research (see also matrix-protein.com, which details the library's structure and regulatory coverage; this article provides updated use-case benchmarks and integration guidelines).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library encompasses compounds acting through a spectrum of mechanisms:

• Receptor Agonists/Antagonists: Modulation of G protein-coupled receptors, nuclear hormone receptors, and ion channels.
• Enzyme Inhibitors: Targeting kinases, proteases, and oxidoreductases crucial for metabolic and signaling pathways.
• Ion Channel Modulators: Regulation of neuronal and cardiac signaling via sodium, potassium, and calcium channels.
• Signal Pathway Regulators: Modulation of PI3K/Akt, MAPK, and NF-κB pathways implicated in cancer and inflammation.

For example, mebendazole—identified in AML screens—targets TUBA1A, inhibits G2/M cell cycle progression, and induces PANoptosis via ZBP1 activation (Yang et al., 2025). Such mechanistic diversity supports broad application in disease modeling and target deconvolution.

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library enables rapid identification of compounds with anti-leukemia activity, as shown in high-throughput screens for PANoptosis in AML models (Yang et al., 2025).
• All 2,320 compounds are pre-dissolved at 10 mM in DMSO, facilitating automated dispensing and minimizing solubility artifacts (APExBIO Product Page).
• Stability is validated for 12 months at -20°C and 24 months at -80°C, ensuring reliable longitudinal studies (APExBIO Product Page).
• Multiple studies have benchmarked this library in target identification and drug repositioning across oncology and neurodegeneration (2xtaqpc.com; this article expands on mechanism-driven screening protocols).
• Compared to custom libraries, the DiscoveryProbe™ FDA-approved Drug Library offers a validated, regulatory-aligned compound set, reducing curation time and increasing translational relevance (lopermide.com; here, we address integration with advanced HTS/HCS platforms).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is optimized for the following research scenarios:

• Drug Repositioning Screening: Identification of new indications for existing drugs, leveraging known safety profiles.
• Pharmacological Target Identification: Deconvolution of mechanisms in cell-based and biochemical assays.
• Cancer Research Drug Screening: Rapid evaluation of anti-proliferative, pro-apoptotic, or pathway-specific effects in oncology models.
• Neurodegenerative Disease Drug Discovery: Exploration of neuroprotective and pathway-modulating compounds in vitro and in vivo.
• Signal Pathway Regulation: Systematic mapping of compound effects on key signaling cascades.

For a detailed exploration of covalent inhibitor mechanisms and library-based assay design, see epglabs.com; our current article focuses on high-content, phenotypic screening and translational relevance.

Common Pitfalls or Misconceptions

• The library is not suitable for primary screening of non-approved or investigational compounds; all entries are clinically approved or pharmacopeia-listed.
• Compounds are provided in DMSO; direct use in aqueous-only or DMSO-sensitive assays may require reformulation.
• The library does not represent all chemical scaffolds—compounds are limited to those approved by major regulatory bodies as of release date.
• HTS/HCS results must be cross-validated with orthogonal assays to confirm phenotypic hits and exclude off-target effects.
• Shipping at room temperature is only validated for non-critical sizes; long-term storage below -20°C is mandatory for stability.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is compatible with automated liquid handling and robotic screening platforms. Key workflow features include:

• Formats: 96-well microplates, deep well plates, and 2D barcoded screw-top tubes for flexible assay setup.
• Concentration & Solvent: Each compound provided at 10 mM in DMSO, suitable for dilution into assay-compatible buffers.
• Stability: 12 months at -20°C; 24 months at -80°C. Minimize freeze-thaw cycles to preserve compound integrity.
• Shipping: On blue ice for evaluation samples; room temperature or blue ice for standard orders as requested.
• Data Integration: Accompanies a digital catalog with compound structures, regulatory status, and mechanistic annotations.

For a technical guide on integrating the library with high-content imaging and machine learning pipelines, see cy3-nhs-ester.com; the present article provides updated recommendations for stability and sample handling.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) from APExBIO is a rigorously curated, regulatory-aligned resource that accelerates drug repositioning, pharmacological target identification, and mechanistic research across multiple disease areas. Its standardized, ready-to-use formats and validated stability parameters enable consistent, reproducible results in high-throughput and high-content screening workflows. As demonstrated in recent studies of AML and beyond, this library underpins rapid translational discoveries by leveraging compounds with established clinical safety. Future updates may expand scaffold diversity and incorporate real-time data curation, further enhancing utility for life sciences researchers (Yang et al., 2025).